Bausch Health Companies Inc
BHC
查看详细走势图
5.880USD
+0.155+2.71%
收盘 02/06, 16:00（美东）报价延迟15分钟
2.18B总市值
6.01市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.71%
5天
+2.44%
1月
-25.57%
6月
+2.08%
今年开始到现在
-15.40%
1年
-8.84%
查看详细走势图
TradingKey Bausch Health Companies Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Bausch Health Companies Inc当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名83/159位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价7.71。中期看，股价处于平稳状态。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Bausch Health Companies Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Bausch Health Companies Inc亮点
亮点风险
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
业绩高增长
公司营业收入稳步增长，连续3年增长18.48%
估值高估
公司最新PE估值6.01，处于3年历史高位
机构加仓
最新机构持股175.10M股，环比增加0.03%
活跃度增加
近期活跃度增加，过去20天平均换手率0.72
分析师目标
根据
7
位分析师
持有
评级
7.714
目标均价
+36.29%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Bausch Health Companies Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Bausch Health Companies Inc简介
Bausch Health Companies Inc. is a global, diversified pharmaceutical company. The Salix segment includes sales in the U.S. of GI products. The International segment includes sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the U.S. and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and OTC products. The Solta Medical segment includes global sales of Solta Medical aesthetic medical devices. The Diversified segment includes sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, dermatology products, generic pharmaceutical products and dentistry products. The Bausch + Lomb segment includes global sales of Bausch + Lomb Vision Care, Surgical and Pharmaceuticals products. Its drug candidate, Larsucosterol binds to and inhibits the activity of DNA methyltransferases, epigenetic enzymes that are elevated and associated with hypermethylation found in AH patients.
公司代码BHC
公司Bausch Health Companies Inc
CEOAppio (Thomas J)
网址https://www.bauschhealth.com/
相关品种
